PEAK6 Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Hold |
0
| – | – | – | 1155 |
|
|
2018
Q1 | – | Sell |
-25,752
| Closed | -$3.27M | – | 1258 |
|
|
2017
Q4 | $3.27M | Buy |
25,752
+23,495
| +1,041% | +$2.99M | 0.02% | 192 |
|
|
2017
Q3 | $265K | Sell |
2,257
-31,309
| -93% | -$3.68M | ﹤0.01% | 669 |
|
|
2017
Q2 | $2.68M | Buy |
33,566
+15,366
| +84% | +$1.23M | 0.02% | 201 |
|
|
2017
Q1 | $933K | Buy |
18,200
+23
| +0.1% | +$1.18K | 0.01% | 374 |
|
|
2016
Q4 | $681K | Buy |
18,177
+2,185
| +14% | +$81.9K | ﹤0.01% | 464 |
|
|
2016
Q3 | $1.08M | Buy |
15,992
+2,746
| +21% | +$186K | 0.01% | 285 |
|
|
2016
Q2 | $735K | Buy |
13,246
+9,463
| +250% | +$525K | 0.01% | 308 |
|
|
2016
Q1 | $237K | Buy |
+3,783
| New | +$237K | ﹤0.01% | 535 |
|
|
2015
Q4 | – | Sell |
-26,972
| Closed | -$2.17M | – | 1161 |
|
|
2015
Q3 | $2.17M | Sell |
26,972
-7,507
| -22% | -$603K | 0.01% | 303 |
|
|
2015
Q2 | $4.13M | Buy |
34,479
+5,333
| +18% | +$639K | 0.02% | 176 |
|
|
2015
Q1 | $3.04M | Buy |
29,146
+9,958
| +52% | +$1.04M | 0.02% | 179 |
|
|
2014
Q4 | $1.86M | Buy |
19,188
+3,739
| +24% | +$363K | 0.01% | 295 |
|
|
2014
Q3 | $1.21M | Buy |
+15,449
| New | +$1.21M | 0.01% | 438 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 1321 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 1469 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 1430 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 1453 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 1378 |
|